News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Cipla Ltd. Tells Merck & Co., Inc. its Anti-AIDS Drug Too Costly in India
April 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MC -- Pharma major Cipla has applied for a "voluntary license" for Merck's anti-HIV drug Isentress saying the drug is exorbitantly priced and is inaccessible to needy patients in India.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Merck & Co.
MORE ON THIS TOPIC
China
AstraZeneca taps China’s CSPC again, betting up to $1.77B to target kidney diseases
July 2, 2026
·
2 min read
·
Tristan Manalac
China
BIO outshines World Cup as biotech celebrates 50th anniversary with a ‘call to action’
June 30, 2026
·
4 min read
·
Annalee Armstrong
China
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
June 30, 2026
·
1 min read
·
Annalee Armstrong
Deals
Lilly deepens relationship with China’s Abbisko for $1.9B biobucks
June 24, 2026
·
2 min read
·
Tristan Manalac
